Status:
UNKNOWN
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.
Lead Sponsor:
Zhong Wang
Collaborating Sponsors:
Shanxi Zhendong Pharmacy Co., Ltd
Conditions:
Safety Surveillance
Adverse Drug Events
Eligibility:
All Genders
Brief Summary
This registry aims to monitor the safety of Qizhi Tongluo Capsules and to identify the potential risk factors for its adverse drug reactions.
Eligibility Criteria
Inclusion
- Patients who use Qizhi Tongluo Capsules in the monitoring hospitals.
Exclusion
- None
Key Trial Info
Start Date :
August 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
30000 Patients enrolled
Trial Details
Trial ID
NCT04479553
Start Date
August 17 2020
End Date
December 1 2023
Last Update
November 15 2022
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Ningming County Hospital of Chinese Medicine
Changzuo, Guangxi, China, 532500
2
Fangchenggang City Hospital of Chinese Medicine
Fangchenggang, Guangxi, China, 538021
3
The First Affiliated Hospital of Guangxi University of Chinese Medicine
Nanning, Guangxi, China, 530023
4
Shanglin County Hospital of Chinese Medicine
Nanning, Guangxi, China, 530500